Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.

Zacks Investment Research • Jun 5, 2026

Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research • Jun 4, 2026

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo.

Business Wire • May 28, 2026

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.

Zacks Investment Research • May 21, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight n.

Business Wire • May 18, 2026

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June.

MarketBeat • May 9, 2026

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.

Zacks Investment Research • May 8, 2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal d.

Business Wire • May 7, 2026